Hypoxia researchers win 2019 Nobel Prize in Medicine

Three scientist friends, working separately, share the prestigious prize.

Hypoxia researchers win 2019 Nobel Prize in Medicine
Photo credit: JONATHAN NACKSTRAND / AFP via Getty Images
  • Nobel recognizes breakthrough insights into cell's perception and response to changes in oxygen levels.
  • Too title oxygen is a problem. Also too much.
  • Their research unveiled a genuine "textbook discovery."

The 2019 Nobel Prize in Medicine has just been awarded to three scientists from the U.S. and U.K. working independently on the same problem: How cells sense and adapt to oxygen availability. They've unveiled the series of molecular events that allow cells to assess and respond to changing levels of available oxygen, with implications in the treatment of cancer, heart attacks, strokes, anemia, and other diseases.

According to the Nobel Assembly, these seminal discoveries "revealed one of life's most essential adaptive processes." The Assembly's Randall Johnson says, "Scientists often toss around this phrase 'textbook discovery.' But I'd say this is really essentially a textbook discovery." He envisions the discovery as "something basic biology students will be learning about when they study — at aged 12 or 13 or younger — biology, and learn the fundamental ways cells work."

Three scientists with three questions

Image source: Paramonov Alexander/Shutterstock

The three scientists who received the 5 a.m. call from Stockholm are Gregg Semenza (Johns Hopkins University), Sir Peter Ratcliffe (Oxford University), and William Kaelin, Jr. (Dana-Farber Cancer Institute/Harvard University). The three shared their work informally over the years in an ongoing conversation that moved the whole field of study forward. Each had his own reason for pursuing his research area, and their interests reflect the far-ranging impact of their findings.

Semenza wondered exactly what it was that cancer cells were seeking when they spread to new areas in the body. He suspected it was oxygen.

As a kidney specialist, Ratcliffe was intrigued by the manner in which the kidney regulated the production of a particular hormone, erythropoietin (EPO), which affects the production of red, oxygen-carrying blood cells in response to changes in levels of available oxygen. Others considered this to be a not-very-interesting question, but Ratcliffe was intrigued.

For Kaelin, it was a pursuit of answers behind a rare genetic form of cancer, Von Hippel-Lindau syndrome (VHL disease), known to involve exaggerated production levels of EPO, and an excess of blood vessels. He had a hunch it was something in cells' then-mysterious oxygen-sensing mechanism malfunctioning.

Why this is important

Image source: Daniel Prudek /Shutterstock

Cells need oxygen to live, and Earth's air-breathing organisms have developed ways to ensure their cells get the amount of oxygen they need. At high altitudes, for example, we produce more red blood cells to accommodate the relative scarcity of air and combat the onset of hypoxia. While a lack of oxygen can be deadly, so too can too much — it may be that an excess of oxygen can be exploited by some cancers, among other issues.

Human bodies have developed a couple of ways to monitor and respond to changes in oxygen levels. The carotid body associated with the large vessels on both sides of the neck have unique cells that sense oxygen levels, and, as noted above, the body produces more oxygen-carrying cells to maximize delivery of what O2 there is when there's not enough. Production of these oxygen-carrying cells is triggered by the production of erythropoietin (EPO) — it's this system that the Nobel winners explored.

A technical glimpse into a three-part puzzle

Image source: DragonTiger8/Shutterstock

The research that led to the Nobel-awarded discovery began back in the 1990s when, Semenza started studying the EPO gene to learn how its production was being controlled. He identified a DNA segment near the EPO gene that appeared to be regulating its production in response to hypoxia. Most interestingly, this DNA, also spotted around the same time by Ratcliffe, wasn't only in kidney cells known to produce EPO, but in all cells.

Eventually Semenza discovered a protein complex that binds to the DNA depending on the amount of oxygen available, and named it hypoxia-inducible factor, or HIF. HIF turned out to be a pair of different DNA-binding proteins, HIF-1α and ARNT.

The amount of HIF-1α increases when oxygen levels are low, apparently due to an oxygen-related reduction in the effect of ubiquitin, a peptide that normally would bind with and quickly decay HIF-1α.

As a result of his immersion in Von Hippel-Lindau research, Ratcliffe discovered why a lack of oxygen could dampen ubiquitin's bite: HIF-1α is tagged for destruction by ubiquitin via the VHL gene. (An absence of the VHL gene causes the disease by allowing the presence of too much HIF-1α.)

This implied an unknown interaction between the VHL gene and HIF-1α and Kaelin and Ratcliffe worked it out. They realized that at normal oxygen levels, two hydroxyl groups were added to two locations in HIF-1α. Aided by oxygen-sensitive enzymes, VHL thus binds to HIF-1α and moderates the production of EPO and the number red blood cells. With either too little or too much oxygen, this balance is upset.

In all, this daisy-chained sets of research has given us a new insight about our bodies — specifically, of the series of molecular events that constantly help our cells assess and respond to changing levels of oxygen. "Textbook discovery," indeed.

From 1.8 million years ago, earliest evidence of human activity found

Scientists discover what our human ancestors were making inside the Wonderwerk Cave in South Africa 1.8 million years ago.

Inside the Kalahari Desert Wonderwerk Cave

Credit: Michael Chazan / Hebrew University of Jerusalem
Surprising Science
  • Researchers find evidence of early tool-making and fire use inside the Wonderwerk Cave in Africa.
  • The scientists date the human activity in the cave to 1.8 million years ago.
  • The evidence is the earliest found yet and advances our understanding of human evolution.
Keep reading Show less

The never-ending trip: LSD flashbacks and a psychedelic disorder that can last forever

A small percentage of people who consume psychedelics experience strange lingering effects, sometimes years after they took the drug.

Digital illustration of a fractal

Imageman Rez via Adobe Stock
Mind & Brain
  • LSD flashbacks have been studied for decades, though scientists still aren't quite sure why some people experience them.
  • A subset of people who take psychedelics and then experience flashbacks develop hallucinogen persisting perception disorder (HPPD), a rare condition in which people experience regular or near-constant psychedelic symptoms.
  • There's currently no cure for the disorder, though some studies suggest medications may alleviate symptoms.
Keep reading Show less

Mind and God: The new science of neurotheology

Studies show that religion and spirituality are positively linked to good mental health. Our research aims to figure out how and why.

Credit: Dan Kitwood via Getty Images
Mind & Brain
  • Neurotheology is a field that unites brain science and psychology with religious belief and practices.
  • There are several indirect and direct mechanisms that link spirituality with improved mental health.
  • Compassion and love are positive emotions that will make your brain healthier.
Keep reading Show less
Surprising Science

Are lab–grown embryos and human hybrids ethical?

This spring, a U.S. and Chinese team announced that it had successfully grown, for the first time, embryos that included both human and monkey cells.

Quantcast